Preclinical trials of a possible new treatment for spinal injuries have yielded positive results that could be a significant boost for patients.
Research carried out by a Miami medical school showed that pharmaceutical company Oxygen Biotherapeutic's third-generation Oxycyte product had a noticeable neuro-protective effect on rats with spinal cord injuries.
The trials found that Oxycyte improves the volume of preserved neuronal tissue in the spinal cord following injury and an improvement in functional recovery six weeks after treatment.
Gerald Klein, chief medical Officer for Oxygen Biotherapeutics, commented: "Having proof-of-concept is a first step toward moving Oxycyte down the spinal cord injury track.
"The positive results observed in both studies may warrant efforts to pursue partnerships to conduct clinical studies of Oxycyte in spinal cord injury in the future."
A study by researchers in Canada recently offered better understanding of how the body reacts to a spinal injury and hope of improved treatment in the future.
They found that serotonin receptors on neurons which operate simple functions were still active in spinal injury patients, allowing the potential for a hormone-based treatment.
News from Serious Law, specialist spinal injury lawyers